|Founder||Colleen Cutcliffe, John Eid and Jim Bullard|
|Headquarters||San Francisco, CA|
Health & Wellness
|Press Contact||Katie Lawera, Jack Taylor PR|
Pendulum Therapeutics is disrupting the probiotics industry. Pioneering the next frontier to restore metabolic health, the biotech company develops microbiome-targeted products that have the power and efficacy of a pharmaceutical with the safety and accessibility of a probiotic. Led by Colleen Cutcliffe, CEO and Co-founder who received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University, Pendulum was founded in 2012 by a diverse team of scientists with deep microbiology, biochemistry, computational and clinical expertise. In a published clinical trial, Pendulum’s flagship product, Pendulum Glucose Control, a medical probiotic, demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in individuals with T2D taking metformin.
Armed with 18 patents and 66 pending, Pendulum has raised $111 million to date from Sequoia Capital, Meritech CapitalTrue Ventures, Khosla Ventures, AME Cloud Ventures, and Mayo Clinic. Pendulum Therapeutics is headquartered in San Francisco.
Colleen Cutcliffe has an impressive background leading and managing biology teams. She’s a scientist with a Ph.D. in Biochemistry and Microbiology from Johns Hopkins University and has held senior positions at bioscience and pharmaceutical firms. She’s also a mom, not to mention our CEO.
Colleen and her two co-founders, John and Jim, saw an opportunity to apply next-generation DNA sequencing technologies and microbiological assays to the emerging microbiome science space. Using these data, they could create metabolic maps of the microbiome and use systems biology to make novel insights into the microbiome. This scientific trio was uniquely positioned to bring new products to the world.
It was her role as a mom, however, that inspired her to team up with her two former colleagues and create Pendulum. Colleen’s first daughter was born eight weeks prematurely. That meant instead of heading home that day with mom and dad, Annabella was whisked away to the NICU for four weeks, receiving multiple doses of antibiotics as a precautionary measure due to her fragile state.
Though antibiotics served an important role in the early days of Annabella’s life, they also decimated her delicate microbiome. As she got older, Colleen began to notice distinct differences in Annabella’s metabolism compared to the rest of their family. She had to deal with food sensitivities in elementary school.
This led Colleen, John and Jim on their journey to find a safe solution to help her daughter and many others who struggle with chronic issues that are the result of a disrupted microbiome. And, this set the stage for the vision of the company to create a new generation of natural products that have proven efficacy.
After nearly a decade of research, Pendulum Glucose Control was born and remains a central part of Colleen and Annabella’s wellness.
Colleen Cutcliffe is the Chief Executive Officer and co-founder of Pendulum. Colleen has more than 25 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology.
Prior to co-founding Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral studies at Northwestern’s Children’s Memorial Hospital. Colleen received her PhD in Biochemistry and Molecular Biology from John Hopkins University and her BA in Biochemistry from Wellesley College.
Jim Bullard is Chief Technology Officer and co-founder of Pendulum. Jim has over a decade of experience leading technical teams in biostatistics and computational biology, and has a passion for experimental design and programming languages.
Prior to co-founding Pendulum, Jim served as a senior staff scientist at Pacific Biosciences. He completed his Ph. in Biostatistics at the University of California, Berkeley and his BA in Computing & Information Systems at Northwestern University.
John Eid is the Chief Science Officer and co-founder of Pendulum. John has led technology development teams for over two decades in diverse areas that include advanced microscopy, single molecule detection and analyses, automated data acquisition systems, biophysical systems modeling, and genome sequencing applications.
Prior to co-founding Pendulum, John was a principal scientist at Pacific Biosciences. John completed his postdoctoral research at the Roland Institute at Harvard University, received his PhD in Biophysics and Computational Biology at the University of Illinois, Urbana Champaign and his BS in Applied and Engineering Physics from Cornell University.
Orville Kolterman, MD, became the chief Medical Officer of Pendulum in 2014. Dr. Kolterman is an internationally respected diabetes expert that has been involved in advancing diabetes care for nearly 50 years. He successfully brought four GLP-1 drugs from research trials to market as the Chief Medical Officer at Amylin Pharmaceuticals. He’s held the role of Adjunct Processor of Medicine at the University of California, San Diego for over 20 years, and is a past President of the California Affiliate of the American Diabetes Association.
Dr. Kolterman completed his residency training in Endocrinology at Stanford University, his MD at the Stanford School of Medicine, and his BA at the University of Kansas.
Loading Related Guides...
Sign In to Continue×
You must be signed in as a media user to from Pendulum and interact with hundreds of other media-ready brands.